Evidence map›Paper›PMID 41817439›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Restriction of Individual Branched-Chain Amino Acids has Distinct Effects on the Development and Progression of Alzheimer's Disease in 3xTg Mice.

Reji Babygirija, Cara L Green, Michelle M Sonsalla, Izabelle Marie F Le, Fan Xiao, Sarah Yandell, Mariah F Calubag, Michaela E Trautman, Anna Tobon, Ryan Matoska and 13 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Reji BabygirijaDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Cara L GreenDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Michelle M SonsallaDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Izabelle Marie F LeDepartment of Biological Chemistry, University of California, Irvine, California, USA.
Fan XiaoDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Sarah YandellDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Mariah F CalubagDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Michaela E TrautmanDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Anna TobonDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Ryan MatoskaDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Chung-Yang YehDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Charles I OparaDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Isaac GrunowDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Diana VerteinDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Sophia SchlorfDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Bailey A KnopfDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Michael J RigbyDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
David A HarrisWisconsin Surgical Laboratory in Metabolism, Department of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Mark P KellerDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Alan D AttieDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Luigi PuglielliDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Cholsoon JangDepartment of Biological Chemistry, University of California, Irvine, California, USA.
Dudley W LammingDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID https://orcid.org/0000-0002-0079-4467

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Pamela K Kreeger · 1985 to 2026
$142.6M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI TOBEY JAMES BETTHAUSER · 2019 to 2026
$34.5M
Genetic Control of Metabolic Flux in Response to DietRC2DK125961 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI ATTIE, ALAN D · 2020 to 2024
$8.1M
Integrated Training For Physician-ScientistsT32GM140935 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anna Huttenlocher, Jeniel E Nett · 2021 to 2026
$6.5M
Spastic paraplegia, neurodegeneration and autism: possible role for AT- 1/SLC33A1?R01NS094154 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI Luigi Puglielli · 2015 to 2026
$4.3M
Creating a region- specific biomolecular atlas of the brain of Alzheimer’s diseaseR01AG078794 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI, Luigi Puglielli · 2022 to 2026
$3.7M
The regulation of health and longevity by branched-chain amino acidsR01AG056771 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Dudley William Lamming · 2018 to 2026
$3.1M
Comparative analysis of geroprotective interventions in established and novel mouse models of Alzheimer's diseaseR01AG062328 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LAMMING, DUDLEY WILLIAM, MERRINS, MATTHEW J. · 2018 to 2022
$2.0M
Elucidating dietary fructose and alcohol interactions during liver cancer developmentR01AA029124 · NIAAA · UNIVERSITY OF CALIFORNIA-IRVINE · PI JANG, CHOLSOON · 2021 to 2025
$2.0M
Safer mTOR inhibition for human geroprotectionU01AG081482 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Adam R Konopka, Dudley William Lamming · 2023 to 2026
$1.8M
ATase1 and ATase2, proteostasis, and neurological diseasesR01GM148487 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Luigi Puglielli · 2023 to 2026
$1.2M
Understanding the roles of prolonged fasting, calorie intake, and mTORC1 in the response to calorie restrictionR01AG094153 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Dudley William Lamming · 2025 to 2026
$1.2M
Alzheimer's Association 23AARG-1029665BLRD VA I01 BX004031BLRD VA IS1 BX005524Dalio PhilanthropiesGlenn Foundation for Medical Research PostdoctoralFellowshipHevolution Foundation HF-AGEAGE-009NCI NIH HHS P30 CA014520NIAAA NIH HHS AA029124NIAAA NIH HHS R01 AA029124NIA NIH HHS AG078794NIA NIH HHS AG088813NIA NIH HHS F31 AG081115NIA NIH HHS F31 AG082504NIA NIH HHS F32 AG077916NIA NIH HHS F32AG077916NIA NIH HHS K99 AG084921NIA NIH HHS K99AG084921NIA NIH HHS P30 AG062715NIA NIH HHS R01 AG056771NIA NIH HHS R01 AG062328NIA NIH HHS R01 AG078794NIA NIH HHS R01 AG094153NIA NIH HHS R03 AG088813NIA NIH HHS U01 AG081482NIDDK NIH HHS DK125961NIDDK NIH HHS RC2 DK125961NIGMS NIH HHS GM148487NIGMS NIH HHS R01 GM148487NIGMS NIH HHS T32 GM140935NIH HHS RC2DK125961NINDS NIH HHS NS094154NINDS NIH HHS R01 NS094154University of Wisconsin Carbone Cancer Center Experimental Animal Pathology Laboratory CA014520U.S. Department of Veterans Affairs I01-BX004031U.S. Department of Veterans Affairs IS1-BX005524UW Distinguished Research FellowWisconsin Alzheimer's Disease Research Center AG062715Wisconsin Nathan Shock Center of Excellence in the Basic Biology of Aging AG092586
6 · The paper itself

Abstract

Dietary protein regulates metabolic health and aging, with many benefits of a low protein diet resulting from reduced consumption of the three branched-chain amino acids (BCAAs), leucine, isoleucine, and valine. Each BCAA has distinct physiological and molecular effects, and while restriction of protein or all three BCAAs improves cognition in mouse models of Alzheimer's disease (AD), the role of each individual BCAA on AD is unknown. Here, we investigate the impact of restricting leucine, isoleucine, or valine on metabolism, AD pathology, molecular signaling, and cognition in male and female 3xTg AD mice. Mice were fed BCAA-restricted diets for nine months starting at six months of age. Restriction of either isoleucine or valine, but not leucine, improved metabolic health. We observed distinct, BCAA-specific effects on AD pathology, molecular signaling, and gene expression in both sexes as well as shared molecular responses in males. Restricting any BCAA improved short-term memory in males, with isoleucine having the strongest effect, while valine restriction led to the greatest cognitive benefits for females. These findings suggest that targeted BCAA restriction, particularly of isoleucine or valine, may form the basis of a novel sex-specific approach to prevent or delay AD.

Indexed as

Alzheimer DiseaseAmino Acids, Branched-ChainAnimalsDisease Models, AnimalDisease ProgressionFemaleIsoleucineLeucineMaleMiceMice, TransgenicValineAmino Acids, Branched-ChainIsoleucineLeucineValineAlzheimer's diseaseautophagybranched chain amino acidsmTORC1

Identifiers

PMID41817439
PMCPMC13248761

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.